<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Soc Bras Med Trop</journal-id><journal-id journal-id-type="iso-abbrev">Rev. Soc. Bras. Med. Trop</journal-id><journal-id journal-id-type="publisher-id">rsbmt</journal-id><journal-title-group><journal-title>Revista da Sociedade Brasileira de Medicina Tropical</journal-title></journal-title-group><issn pub-type="ppub">0037-8682</issn><issn pub-type="epub">1678-9849</issn><publisher><publisher-name>Sociedade Brasileira de Medicina Tropical - SBMT</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7156252</article-id><article-id pub-id-type="doi">10.1590/0037-8682-0155-2020</article-id><article-id pub-id-type="other">00904</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Monteiro</surname><given-names>Wuelton Marcelo</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Brito-Sousa</surname><given-names>Jose Diego</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ba&#x000ed;a-da-Silva</surname><given-names>Djane</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>de Melo</surname><given-names>Gisely Cardoso</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Siqueira</surname><given-names>Andr&#x000e9; Machado</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Val</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Daniel-Ribeiro</surname><given-names>Cl&#x000e1;udio Tadeu</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4690-4841</contrib-id><name><surname>Guimar&#x000e3;es Lacerda</surname><given-names>Marcus Vinicius</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Funda&#x000e7;&#x000e3;o de Medicina Tropical Dr. Heitor Vieira Dourado, Departamento de Ensino e Pesquisa, Manaus, AM, Brasil.</aff><aff id="aff2">
<label>2</label>Universidade do Estado do Amazonas, Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Medicina Tropical, Manaus, AM, Brasil.</aff><aff id="aff3">
<label>3</label>Instituto Nacional de Infectologia Carlos Chagas, Rio de Janeiro, RJ, Brasil. </aff><aff id="aff4">
<label>4</label>Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro, RJ. Brasil.</aff><aff id="aff5">
<label>5</label>Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Instituto de Pesquisas Le&#x000f4;nidas e Maria Deane, Manaus, AM, Brasil.</aff><author-notes><corresp id="c1"><bold>Corresponding author:</bold> Marcus Vinicius Guimar&#x000e3;es Lacerda. <bold>e-mail</bold>: <email>marcuslacerda.br@gmail.com</email></corresp><fn fn-type="con" id="fn2"><p>
<bold>Autors&#x02019; contribution:</bold> All authors contribute to conceptualization, writing and review.</p></fn><fn fn-type="COI-statement" id="fn3"><p>
<bold>Conflict of interest:</bold> The authors declare that there is no conflict of interest.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>4</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>53</volume><elocation-id>e20200155</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2020</year></date></history><permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p></license></permissions><counts><fig-count count="0"/><table-count count="1"/><equation-count count="0"/><ref-count count="12"/></counts></article-meta></front><body><p>Dear Editor:</p><p>The first cases of the new coronavirus (COVID-19) were reported in December, 2019, when a group of patients was admitted to hospitals with an initial diagnosis of pneumonia of unknown etiology<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>. Initially, the outbreak of the new SARSCoV-2 coronavirus (coronavirus disease 2019; formerly 2019-nCoV) was centralized in the province of Hubei, Republic of China, and later spread to many other countries<xref rid="B2" ref-type="bibr">
<sup>2</sup>
</xref>. SARS-CoV-2 infection appears to cause a wide range of symptoms, encompassing asymptomatic infection, mild infections of the upper respiratory tract, severe viral pneumonia, respiratory failure, multiple organ failure and death<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>. Some studies have shown detailed clinical features of some patients with SARS-CoV-2<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>. Of the 44,672 laboratory confirmed patients in China, almost 5% had critical illnesses and almost 50% of the critical patients died, with the overall rate of fatal cases (2.3%) being higher than that observed for seasonal influenza<xref rid="B5" ref-type="bibr">
<sup>5</sup>
</xref>. Most deaths involved older adults, many of whom had underlying chronic diseases<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref>, while children are less likely to develop severe infections<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref>. Despite there being no available data so far, anecdotal data from Italy showed a huge number of deaths in the elderly, paving the way for drastic control measures worldwide and compassionate use of drugs in severe cases. </p><p>Chloroquine (CQ) was unequivocally demonstrated to have <italic>in vitro</italic> inhibiting effects on SARS-CoV-2 infection<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref> and was precociously publicized as having a beneficial effect in COVID-19 patients after a study conducted in Marseille, France showed a viral load reduction in COVID-19 patients<xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref>. Since there is no specific antiviral therapy for coronavirus infections to date, the announcement of partial and fragile data led to precipitated political manifestations by major government leaders and contributed to uncoordinated recommendations of the drug to severe patients. Considering CQ&#x02019;s low costs, good safety profile, <italic>in vitro</italic> activity against other viral diseases, preexisting supply chain with potential for public and private augmented production, and knowledge on specificity and management of side effects accumulated for decades of use for anti-malarial use, it is expected that clinical assays will be promptly designed to multicentrically evaluate the actual potential of the drug for treating severe COVID-19 cases.</p><p>CQ sulfate and phosphate salts and hydroxychloroquine (HCQ) have both been used as antimalarial drugs for decades. HCQ, a derivative of CQ, was first synthesized in 1946 by the introduction of an N-hydroxy-ethyl side chain in place of QC's N-diethyl group and proved to be less (~40%) toxic during prolonged use and is therefore recommended for the treatment of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, in which patients are exposed to the drug for months or eventually for years<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>. </p><p>Several studies are currently being carried out with CQ and HCQ, however only a few of the researchers published preliminary results, while other studies were canceled, mainly due to the reduction of cases in China. As of the preparation of this manuscript (March 26<sup>th</sup>, 2020), only 13 trials have been registered on the ClinicalTrials.gov platform, with 2 studies being carried out in Brazil using CQ or HCQ and azithromycin.Additionally, 22 trials have been registered on the Chinese Clinical Trial Registry, of which 6 are stated as having been withdrawn (http://www.chictr.org.cn/index.aspx). The large number of studies conducted with this drug shows that the scientific community is making a great effort to clarify the role of these drugs in reducing the mortality associated with COVID-19, but that effort is probably not being sufficiently well coordinated yet.</p><p>Different treatments and lengths of treatment, and dose regimes have been reported. However, there is an urgent need for adaptive clinical trial designs in order to properly - and rapidly - respond to different questions observed during Covid-19 pandemic. Adaptive clinical trials have contributed greatly to advances in patient care byincreasing the efficiency and flexibility of randomized clinical trials, reducing costs and increasing the likelihood of finding a true benefit, if any, of the intervention being studied<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. Several deficiencies in traditional randomized clinical trials (RCTs) have been observed, including larger sample sizes and lengthy duration, lack of power to evaluate global efficacy or in important subgroups, and cost, which all limit medical innovation especially in our emergency scenario<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>. </p><p>Finally, there is a need for urgent answers that should not be limited to our current scenario, but should also be used to prepare for future Covid-19 pandemics, considering that cases will only be available now and no studies will be feasible in the meantime. This has happened in China, where many trials were interrupted because no more cases were appearing by the time studies were ready to get started. Currently, several obstacles still need to be discussed and addressed (<xref rid="t1" ref-type="table">Table 1</xref>): the use of a placebo group in severe patients to effectively show treatment efficacy; lack of instantaneous funding; need for timely protocol approval by ethical boards worldwide; the use of multicentric studies rather than single-center studies, and compliancy with good clinical practices, in order to promptly find answers while the pandemic is still ongoing. The use of a placebo in patients with critical disaease, which would be the best way to prove the efficacy of the different interventions being tested, could be considered unethical by many since there are compassionate clinical conducts to treat such cases arund the globe. At the moment, we all believe that such placebo-controlled trials should only be carried out with non-severe cohorts.</p><p>
<table-wrap id="t1" orientation="portrait" position="float"><label>TABLE 1:</label><caption><title>Open questions to be answered regarding the use of chloroquine against Covid-19.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Research question</th><th align="left" rowspan="1" colspan="1">Expected outcome</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Does it work to prevent infection?</bold>
</td><td align="left" rowspan="2" colspan="1">Decrease in confirmed infections in a cohort of uninfected individuals</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Pre- and post-exposure prophylaxis</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Does it work to prevent clinical disease?</bold>
</td><td align="left" rowspan="2" colspan="1">Decrease in proportion of patients that develop clinical symptoms </td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Clinical disease prevention</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Does it work to prevent clinical severity?</bold>
</td><td align="left" rowspan="2" colspan="1">Decrease in proportion of patients with onset of severe disease (SARS criteria, need for respiratory support, ICU admission, post-infection respiratory sequelae)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Severe clinical disease prevention</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Does it work to prevent death?</bold>
</td><td align="left" rowspan="2" colspan="1">Reduced mortality in severe cases (hospitalized patients)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Mortality prevention</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Does it decrease viral load in blood and secretions?</bold>
</td><td align="left" rowspan="2" colspan="1">Rapid viral clearance after treatment</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Viral load</italic>
</td></tr></tbody></table></table-wrap>
</p></body><back><fn-group><fn fn-type="supported-by" id="fn1"><p>
<bold>Financial Support:</bold> WMM, CTDR and MVGL are CNPq research fellows. JDB-S is funded by post-graduate fellowship from the Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado do Amazonas (FAPEAM). AMS is a young research fellow funded by the Funda&#x000e7;&#x000e3;o de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). CTDR is a Scientist at Funda&#x000e7;&#x000e3;o Carlos Chagas Filho-FAPERJ. This study was funded by FAPEAM.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">31986257</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><etal/></person-group><article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title><source>N Engl J Med</source><day>24</day><month>1</month><year>2020</year><volume>382</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Gan</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings</article-title><source>Eur J Radiol</source><year>2020</year></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><day>25</day><month>3</month><year>2020</year></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group><article-title>Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention</article-title><source>J Am Med Assoc</source><year>2020</year></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title><source>Lancet Respir Med</source><day>25</day><month>3</month><year>2020</year></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Infection in Children</article-title><source>N Engl J Med</source><day>18</day><month>3</month><year>2020</year></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><fpage>16</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">32194981</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>J-C</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Meddeb</surname><given-names>L</given-names></name><name><surname>Mailhe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2020</year></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>HS</given-names></name><name><surname>Im</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>JY</given-names></name><name><surname>Bae</surname><given-names>KS</given-names></name><name><surname>Klein</surname><given-names>TA</given-names></name><name><surname>Yeom</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>1468</fpage><lpage>1475</lpage><pub-id pub-id-type="pmid">19188392</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Mehta</surname><given-names>C</given-names></name></person-group><article-title>Adaptive Designs for Clinical Trials</article-title><source>N Engl J Med</source><day>06</day><month>7</month><year>2016</year><volume>375</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">27406349</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>P</given-names></name><name><surname>Bretz</surname><given-names>F</given-names></name><name><surname>Dragalin</surname><given-names>V</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>F</given-names></name><name><surname>Wassmer</surname><given-names>G</given-names></name></person-group><article-title>Twenty-five years of confirmatory adaptive designs: Opportunities and pitfalls</article-title><source>Stat Med</source><year>2016</year></element-citation></ref></ref-list></back></article>